These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 19246907

  • 1. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Takase T, Ohbayashi T.
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A, Gauthier S, Perdomo C.
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 5. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar 31; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.
    Curr Med Res Opin; 2007 Dec 31; 23(12):3153-65. PubMed ID: 17988434
    [Abstract] [Full Text] [Related]

  • 9. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
    Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T.
    Dement Geriatr Cogn Disord; 2008 Dec 31; 25(5):399-407. PubMed ID: 18391486
    [Abstract] [Full Text] [Related]

  • 10. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R.
    Int J Geriatr Psychiatry; 2004 Jan 31; 19(1):58-67. PubMed ID: 14716700
    [Abstract] [Full Text] [Related]

  • 11. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.
    Pharmacogenet Genomics; 2006 Nov 31; 16(11):771-4. PubMed ID: 17047484
    [Abstract] [Full Text] [Related]

  • 12. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
    Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K.
    Curr Med Res Opin; 2009 Nov 31; 25(11):2577-87. PubMed ID: 19735164
    [Abstract] [Full Text] [Related]

  • 13. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
    Froelich L, Gertz HJ, Heun R, Heuser I, Jendroska K, Kornhuber J, Kurz A, Mueller-Thomsen T, Ries F, Waechtler C, Metz M, Goebel C.
    Dement Geriatr Cogn Disord; 2004 Nov 31; 18(1):37-43. PubMed ID: 15084792
    [Abstract] [Full Text] [Related]

  • 14. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.
    Curr Med Res Opin; 2005 Aug 31; 21(8):1317-27. PubMed ID: 16083542
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

  • 19. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R.
    Dement Geriatr Cogn Disord; 2006 May 05; 21(5-6):353-63. PubMed ID: 16508298
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.